Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 3, 2013

GSK Grabs MorphoSys RA Candidate in Deal Worth Up to $548M

  • MorphoSys and GlaxoSmithKline have entered an agreement to develop and commercialize MOR103, the former firm’s HuCAL-derived antibody against GM-CSF, which has concluded Phase I/II development for mild to moderate rheumatoid arthritis (RA).

    Through this agreement, GSK is responsible for all future development and commercialization of MOR103, for which MorphoSys will receive an up-front payment of €22.5 million (approximately $29.2 million).

    As certain developmental, regulatory, commercial, and sales-based milestones are achieved, MorphoSys would also be eligible for additional payments of up to €423 million ($548 million), plus tiered, double-digit royalties on net sales.

    MorphoSys said it has adjusted its financial guidance for the year, as it predicts expected revenues to jump from €68 million ($89 million) to €72 million ($93.6 million) as a result of this GSK deal.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »